MACDOUGALL BIOMEDICAL COMMUNICATIONS
MacDougall Biomedical Communications (MBI) is a team of experienced, multi-talented consultants spanning two locations – Boston and Munich – providing an integrated suite of media relations, investor relations, corporate communications and creative design services to life sciences companies of all sizes and stages, public and private. MBI offers its clients an unparalleled global network of contacts and expertise addressing all key audiences: investors, media, partners, and the medical and scientific communities at large. For more information, visit us at www.macbiocom.com.
MACDOUGALL BIOMEDICAL COMMUNICATIONS
Industry:
Advertising Consulting Health Care Information Technology Internet Marketing
Founded:
2002-01-01
Address:
Wellesley, Massachusetts, United States
Country:
United States
Website Url:
http://www.macbiocom.com
Total Employee:
11+
Status:
Active
Contact:
(781) 235-3060
Email Addresses:
[email protected]
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Google Google Cloud Network Solutions DNS MailChimp SPF Google Cloud Iowa
Similar Organizations
C3i Solutions
C3i Solutions is a multi-channel customer engagement services provider.
MyDoctorCare
Why Is It So Hard To Find A Doctor When You Need One? My name is Zinovi Kurolap. I am the CEO of MyDoctorCare.
Current Employees Featured
Official Site Inspections
http://www.macbiocom.com Semrush global rank: 4.03 M Semrush visits lastest month: 1.11 K
- Host name: 253.140.174.34.bc.googleusercontent.com
- IP address: 34.174.140.253
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "MacDougall Biomedical Communications"
MacDougall Farewell - MacDougall
May 31, 2024 · MacDougall Advisors has closed its operations as of May 31, 2024. We want to express our deepest gratitude to the life science and biotech industry that we’ve served these past 22 years. To our clients and former …See details»
MacDougall Biomedical Communications
We help client companies, institutions and entrepreneurs craft, brand and deliver messages to support their quest to improve healthcare. View contacts for …See details»
MacDougall | Natick MA - Facebook
MacDougall, Natick, Massachusetts. 99 likes · 1 talking about this · 15 were here. A team of experienced, multi-talented consultants providing an...See details»
MacDougall Biomedical Communications - ZoomInfo
Apr 27, 2022 · MBI offers its clients an unparalleled global network of contacts and expertise addressing all key audiences: investors, media, partners, and the medical and scientific …See details»
MacDougall Biomedical Communications: Informationen …
MacDougall is a team of experienced, multi-talented consultants providing an integrated suite of services to organizations creating innovation in healthcare to help patients lead more …See details»
MacDougall - We're hiring for two positions in our Boston.
Feb 18, 2015 · We're hiring for two positions in our Boston and SF offices: Director or VP of Media Relations/Scientific Communications: http://macbiocom.com/job-listings/mbi-director …See details»
TAE Life Sciences and CNAO (National Center of …
Oct 27, 2020 · FOOTHILL RANCH, Calif.-- ( BUSINESS WIRE )-- TAE Life Sciences (TLS), a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based …See details»
Cerecor Inc. Names Uli Hacksell, Chairman of Cerecor and …
Cerecor Inc. is a Baltimore-based biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with …See details»
CRISPR Therapeutics Raises Additional $64… | CRISPR …
BASEL, Switzerland and CAMBRIDGE, Massachusetts – April 29, 2015 – CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology …See details»
Immunome Announces Additional $4.3 Million Award by …
May 20, 2021 · Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are …See details»
macbiocom - YouTube
MacDougall Biomedical Communications' sole focus is to fulfill the unique communications needs of companies and organizations that are developing products or...See details»
Synlogic Announces Promotion of Antoine 'Tony' Awad to …
Jul 30, 2020 · As Chief Operating Officer, Tony will drive Synlogic's end to end development & manufacturing organization and supply chain as well as have broader corporate operations …See details»
MacDougall - Learn more about the MacDougall team, and …
Learn more about the MacDougall team, and our Senior Director, Megan. https://bit.ly/3hBDRot #MacBios #MacBioCom #MacDougallbio #Biotech #Munich #Boston...See details»
Tectonic Therapeutic Strengthens Leadership Team
Jul 19, 2022 · Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G …See details»
CARB-X injects up to $48 million to accelerate first …
CARB-X aims to invest up to $450 million over five years with the goal of accelerating the preclinical discovery and development of at least 20 new antibacterial products and …See details»
Imeglimin’s Innovative Mitochondria-Targeted Mechanism …
LYON, France-- (BUSINESS WIRE)-- POXEL SA (Euronext: POXEL) a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today …See details»
Prokarium Expands R&D Capabilities with London …
LONDON, UK – January 26, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, has entered into an agreement, through Imperial …See details»
Overland Pharmaceuticals Appoints Roger Luo, Ph.D. as …
Aug 2, 2021 · Overland Pharmaceuticals is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world.See details»
Unique Mitochondria-targeting Mechanism of Action …
Imeglimin has been proven to have a beneficial effect on both insulin sensitizing and insulin secretion defects in type 2 diabetes. The new data demonstrate the drug candidate’s positive …See details»
OcuTerra
Creating a clear vision for the treatment of ophthalmic diseases. Potential to address tremendous unmet need by enabling earlier, non-invasive treatment of diabetic retinopathy Administered …See details»